Deegen Deegen P P Thomas Thomas O O Nolan-Stevaux Nolan-Stevaux O O The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer Clin Cancer Res Clin Cancer Res 2021 2021 27 27 2928 2928 2937 2937 supplied-pmid 33504551? This evidence concerns the gene FOLH1 and prostate cancer.